



## PUBLICATIONS

---

1. **Membrane stabilizers and excitability in isolated rat soleus muscle.** Albeson C, Clarke D, Cookson J, Cunningham S, Kohn PG, Kumari P, Miller C, Woodham S. *J of Physiol* 1982;334:36-37P.
2. **The measurement of broadband ultrasonic attenuation in cancellous bone.** Langton CM, Miller CG, Porter RW, Palmer SB. *British J. of Radiol.* 1985; 58:691.
3. **Back pain and trunk list.** Porter RW, Miller CG. *Spine* 1986; 11(6):596-600.
4. **Ultrasound attenuation in the os calcis.** Porter RW, Miller CG, Langton CM, Rogers L, Palmer SB, In *Back Pain: New methods for clinical investigation and assessment.* Edited by Hukins DWL, Mulholland RC. 1986 Manchester University Press.
5. **The relationship between broadband ultrasonic attenuation in the os calcis and post-menopausal fractures.** Porter RW, Miller CG, Langton CM. *Bone* 1987; 8:45-55.
6. **The prediction of fracture of the proximal femur by broadband ultrasonic attenuation.** Miller CG, Porter RW. In *The International Symposium on Osteoporosis, Denmark 1987.* Edited by Christiansen C, Johansen JS, Riis BJ.
7. **Broadband ultrasonic attenuation as a predictive index for hip fracture in the elderly.** Miller CG, Porter RW. In *Ultrasonic Assessment of Bone.* Edited by Palmer SB, Langton CM. IOP Publishing Short meeting series No. 6. 1987.
8. **Specificity and sensitivity of ultrasound attenuation in bone.** Murray SA, Miller CG, Kanis JA, in *Ultrasonic studies of bone.* Edited by Palmer SB, Langton CM. IOP Publishing Short meeting series No. 6, 1987.
9. **The prediction of fracture of the proximal femur by broadband ultrasonic attenuation.** Miller CG, Porter RW. *Clin. Phys. Physiol. Meas.* 1988; 9(2):180.
10. **The prediction of hip fracture in the elderly by the measurement of broadband ultrasonic attenuation through the os calcis.** Miller CG, Porter RW, Smith PC, Grainger D, Palmer SB. In *Osteoporosis and Bone Mineral Measurement.* Edited by Ring EFG, Evans WD, Dixon AS Institute of Physical Sciences in Medicine 1989, 143-46.
11. **Neurogenic claudication and root claudication treated with calcitonin: A double-blind trial.** Porter RW, Miller CG. *Spine* 1989; 13(9):1061-4.
12. **Ketorolac transfer into CSF.** O' Sullivan GM, Rice ASC, Miller C, Lloyd J, Bullingham RES. *European Journal Clinical Pharmacology* 1989; 365.
13. **Assessment of broadband ultrasonic attenuation in the os calcis in vitro.** McCloskey EV, Murray SA, Charlesworth D, Miller C, Fordham J, Clifford K, Atkins R, Kanis JA. *Clinical Science* 1990; 78:221-5.
14. **Broadband ultrasonic attenuation in the os calcis: relationship to bone mineral at other sites.** McCloskey EV, Murray SA, Miller C, Charlesworth D, Tindale W, O'Doherty DP, Bickerstaff DR, Hamdy NAT, Kanis JA. *Clinical Science* 1990; 78:227-33.
15. **Prediction of hip fracture in elderly women: A prospective study.** Miller CG, Porter RW, Grainger D, Palmer SB. In *Osteoporosis 1990. The third international symposium on osteoporosis, Copenhagen, Denmark.* Edited by Christiansen C, Overgaard K.



## PUBLICATIONS - CONTINUED

---

16. **Prediction of hip fracture in elderly women: A prospective study.** Porter RW, Miller CG, Grainger D, Palmer SB. British Medical Journal 1990; 301:638-41.
17. **Prediction of hip fracture in elderly women.** Miller CG, Porter RW. British Medical Journal 1991; 302:50 (letter to the editor).
18. **Bioavailability of two formulations of Naproxen enteric-coated 500 mg tablets in fasting and postprandial male volunteers following a single dose.** Miller CG, Bullingham RES, Jonkman JHG. Current Therapeutic Research 1991; 49(5):740-9.
19. **A double-blind study of the speed of onset of analgesia following the intramuscular administration of ketorolac tromethamine in comparison to intramuscular morphine and placebo.** Rice ASC, Lloyd J, Miller CG, Bullingham RE, O'Sullivan GM. Anesthesia 1991; 46; 7:541-44.
20. **Ultrasonic measurements in the calcaneus: a comparison of two commercial scanners.** Ramalingam T, Herd RJM, Blake GM, Miller CG, Fogelman I. in Current Research in Osteoporosis and Bone Mineral Measurement II: 1992 Ring EFJ Br. Inst Radiol 1992.
21. **Can ultrasonic measurements in the calcaneus predict osteopenia in the axial skeleton?** Herd RJM, Blake GM, Miller CG, Fogelman I. in Current Research in Osteoporosis and Bone Mineral Measurement II: 1992. Ring EFJ Br. Inst Radiol 1992.
22. **Ultrasonic velocity measurements through the calcaneus: which velocity should be measured?** Miller CG, Herd RJM, Ramalingam T, Blake GM, Fogelman I. in Current Research in Osteoporosis and Bone Mineral Measurement II: 1992 Ring EFJ Br. Inst Radiol 1992.
23. **Ultrasonic velocity measurements through the calcaneus: which velocity should be measured?** Miller CG, Herd RJM, Ramalingam T, Blake GM, Fogelman I. Osteoporosis International 1993; 3(1):31-5.
24. **Bone density measurements in clinical trials: the challenge of ensuring optimal data.** Miller CG. British Journal of Clinical Research 1993; 4:113-20.
25. **Measurement of postmenopausal bone loss with a new contact ultrasound system.** Herd RJM, Blake GM, Ramalingam T, Miller CG, Ryan PJ, Fogelman I. Calcified Tissue International 1993;53(3):153-7.
26. **Should broadband ultrasonic attenuation be normalized for the width of the calcaneus?** Herd RJM, Blake GM, Miller CG, Fogelman I. in Current Research in Osteoporosis and Bone Mineral Measurement III: 1994 Ring EFJ Br. Inst Radiol 1994.
27. **Optimal bone density measurements in clinical trials.** Miller CG, in Current Research in Osteoporosis and Bone Mineral Measurement III: 1994 Ring EFJ Br. Inst Radiol 1994.
28. **The ultrasonic assessment of osteopenia as defined by dual X-ray absorptiometry.** Herd RJM, Blake GM, Miller CG, Parker JC, Fogelman I. British Journal of Radiology 1994; 67(799):631-5.
29. **Entrance criteria for clinical trials with DEXA.** Miller CG, Barden HS. Journal of Bone and Mineral Research 1994; 9(Supplement 1):S209.



## PUBLICATIONS - CONTINUED

30. **Cross-calibration of Dual Energy X-ray densitometers for a large, multi-centre genetic study of osteoporosis.** Reid DM, Mackay I, Wilkinson S, Miller C, Schuette DG, Compston J, Cooper C, Duncan E, Galwey N, Keen R, Langdahl B, McLellan A, Pols H, Uitterlinden A, Riordan JO, Wass JAH, Ralston SH, Bennett ST. *Osteoporosis International* 2006;17(1):125-32.
31. **Vertebral morphometry using radiographs: comparison of manual and digitized images in expert software.** Miller CG, Ohlsson S, Borg J, Johnell O. *Osteoporosis International* 1996; 6(Supplement 1).
32. **New DEXA quality control methodology in clinical trials.** Miller CG, Lyons AR, Pye D, Fasano G, Horne S. *Journal of Bone and Mineral Research* 1997;12(Supplement 1):S5377.
33. **Dual energy x-ray absorptiometry (DXA) transmission methodology in clinical trials.** Miller CG, Lyons AR, Pye DW, Blaze M, Fasano GA, Horne S. *Drug Information Journal* 1998; 32-4.
34. **A new hydroxyapatite spine phantom.** Nord RH, Bisek JP, Miller CG. *Osteoporosis International* 1997; 7:287.
35. **Heel ultrasound reference data for Caucasian women in the USA.** Rosen C, McClung M, Gallagher C, Baldwin D, Faulkner K, Trempe J, Miller C. *Journal of Clinical Densitometry.* 1998; 1(1):107.
36. **Instrument measurements in clinical trials - presenting the right image.** Miller CG. *European Pharmaceutical Contractor.* May 1998:84-9.
37. **Methodology for the clinical assessment of medical instrumentation: evaluating ultrasonometers.** Miller CG. *Journal of Clinical Densitometry.* 1998; 1(3):309-16.
38. **Cross calibration, precision and patient dose measurements in preparation for clinical trials using dual energy X-ray absorptiometry of the lumbar spine.** Cawte SA, Pearson D, Green DJ, Masalanka WB, Miller CG, Rogers AT. *British Journal of Radiology.* 1999; 72(856):354-62.
39. **Precision of DXA measurements of the spine and total hip in adolescents.** Miller CG, Pak J, Caminis JN. *Journal of Bone and Mineral Research* 2001; 16(Supplement 1):S317.
40. **The use of medical imaging in clinical trials.** Miller CG. *SoCRA Source* November 2001; 30:26-8.
41. **Image Management in Clinical Trials.** Miller CG. *Business Briefing: Pharmatech* 2002.
42. **Scanning data for clinical information.** Miller C, Noever K. *Good Clinical Practices Journal.* 2003. 10(9):21-4.
43. **Reading Medical Images in Oncology Clinical Trials.** Miller CG, Noever K. *European Pharmaceutical Contractor.* Summer 2004; 95-100.
44. **Cross-calibration of Dual Energy X-Ray densitometers for a large multi-centre genetic study of osteoporosis.** Reid DM, Mackay I, Wilkinson S, Miller C, Schuette DG, Compston J, Cooper C, Duncan E, Galwey N, Keen R, Langdahl B, McLellan A, Pols H, Uitterlinden A, Riordan JO, Waas JAH, Ralston SH, Bennett SH. *Osteoporosis International* 2005.



## PUBLICATIONS - CONTINUED

45. **Medical Imaging Core Laboratories.** Applied Clinical Trials. Miller CG. 2<sup>nd</sup> Oct 2005  
<http://www.appliedclinicaltrials.com/appliedclinicaltrials/author/authorDetail.jsp?id=22742>
46. **Visceral and Subcutaneous Adiposity Measurements in Adults: Influence of Measurement Site.** Ellis KJ, Grund B, Visnegarwala F, Thackeray L, Miller CG, Chesson CE, El-Sadr W, Carr A. Obesity 2007;15(6):1441-7.
47. **Education Alternatives for imaging techniques in clinical trials.** Miller CG, Wertz K. World Pharma Network. July 2007; 42-3.
48. **Same Language, Different Message: The American Way from a British Perspective. Presentation at the Annual Meeting of the Institute of Clinical Research, April 2008** (Birmingham). Pub. CRFocus; June 2008; 19(6):75-6.
49. **Medical imaging and electronic data capture in clinical trials: the future paradigm.** Miller CG. International Pharmaceutical Industry (IPI) Spring 2009; 30-32.
50. **Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations.** Fisher M, Feuerstein G, Howells et al. Stroke 2009; 40(6):2244-50.
51. **Development of a clinical workflow tool to enhance the detection of vertebral fractures.** Brett A, Miller CG, Hayes CW, Krasnow J, Ozanian T, Abrams K, Block J, van Kuijk C. Spine 2009;34(22):2437-43.
52. **Quantitative Imaging Test Approval and Biomarker Qualification: Interrelated but Distinct Activities.** Buckler, AJ, Bresolin L, Dunnick NR, Sullivan DC, Aerts HJ, Bendriem B, Bendtsen C, Boellaard R, Boone JM, Cole PE, Conklin JJ, Dorfman GS, Douglas PS, Eidsaunet W, Elsinger C, Frank RA, Gatsonis C, Giger ML, Gupta SN, Gustafson D, Hoekstra OS, Jackson EF, Karam L, Kelloff GJ, Kinahan PE, McLennan G, Miller CG, Mozley PD, Muller KE, Patt R, Raunig D, Rosen M, Rupani H, Schwartz LH, Siegel BA, Sorensen AG, Wahl RL, Waterton JC, Wolf W, Zahlmann G, Zimmerman B. " Radiology. 2011. 259(3): 875-884.
53. **Mechanism of Action Study to Evaluate the Effect of Rosiglitazone on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus: Rationale, Study Design and Baseline Characteristics.** Lorraine A. Fitzpatrick, John P. Bilezikian, Margaret Wooddell, Gitanjali Paula, Nikheel S. Kolatkar, Antonio J. Ninoa, Colin G. Miller, Cesar E. Bogadof, Claude D. Arnaud, Alexander R. Cobitza Journal of Drug Assessment 2012 Vol 1; 11-19.
54. **A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The ORACAL trial.** Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS. J Bone Miner Res. 2012 Mar 21. 27(8):1821-1829.
55. **Metrics in Medical Imaging. Changing the picture.** HJ Yu, CG Miller, D Flitcraft. Monitor. (Peer reviewed), Aug 2012: 36 – 40.
56. **A 2-Year Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Oral Selective Inos Inhibitor, Cindunistat, In Patients with Symptomatic Osteoarthritis of the Knee.** MP. Hellio Le Graverand, R. Clemmer, P. Redifer, R. Brunell, C.W. Hayes, K. Brandt, S. Abramson, P. Manning, C. Miller, and E Vignon. Ann Rheum Dis. 2012 Nov 10. [Epub ahead of print] PubMed PMID: 23144445.
57. **Considerations when designing a disease-modifying osteoarthritis drug (DMOAD) trial using radiography.** Hellio Le Graverand MP, Clemmer RS, Brunell RM, Hayes CW, Miller CG, Vignon E. Semin Arthritis Rheum. 2013 Jan 1. doi:pii: S0049-0172(12)00278-8. 10.1016/j.semarthrit.2012.11.006. [Epub ahead of print] PMID: 23290692.



## PUBLICATIONS - CONTINUED

58. **Rate of adjudication of radiological progression in rheumatoid arthritis randomized controlled trials depending on preset limits of agreement: a pooled analysis from 15 randomized trials.** Navarro-Compán V, Landewé R, Ahmad HA, Miller CG, Xu D, Wolterbeek R, van der Heijde D. *Rheumatology (Oxford)*. 2013 Jan 16. [Epub ahead of print] PMID: 23329683.
59. **Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women with Type 2 Diabetes Mellitus** Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA. *J Clin Endocrinol Metab*, April 2013, 98(4):1519–1528.
60. **Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC).** Navarro-Compán V, van der Heijde D, Ahmad HA, Miller CG, Wolterbeek R, Landewé R. *Ann Rheum Dis*. 2013 Apr 20. [Epub ahead of print] PMID: 23606704.
61. **Atlas-Based Liver Segmentation and Hepatic Fat-Fraction Assessment for Clinical Trials.** Yan, Z, Zhang, S., Tan, C., Belaroussi, B, Yu, H.J., Miller C., Metaxas, D. *Computerized Medical Imaging and Graphics*, 2014.
62. **Imaging of cartilage and bone: promises and pitfalls in clinical trials of osteoarthritis.** Eckstein F., Guermazi A., Gold G., Duryea J., Hellio Le Graverand MP., Wirth W., Miller CG. *Osteoarthritis and Cartilage*. 22(10):1516-32. doi: 10.1016/j.joca.2014.06.023. PMID: 25278061 [PubMed - in process] Free PMC Article. Oct 2014.
63. **The current status of imaging in anti-NGF clinical trials.** Miller, C.G., Guermazi, A., Roemer, F.W. *Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S3 - S7.* doi: 10.1016/j.joca.2014.09.002. Jan 2015.
64. **Imaging atlas for eligibility and on-study safety of potential knee adverse events in anti-NGF studies (Part 1).** Roemer, F.W., Hayes, C.W., Miller, C.G., Hoover, K., Guermazi, A. *Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S22 - S42.* doi: 10.1016/j.joca.2014.09.002. Jan 2015.
65. **Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2).** Roemer, F.W., Hayes, C.W., Miller, C.G., Hoover, K., Guermazi, A. *Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S43 - S58.* doi: 10.1016/j.joca.2014.09.002. Jan 2015.
66. **Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (Part 3).** Roemer, F.W., Hayes, C.W., Miller, C.G., Hoover, K., Guermazi, A. *Osteoarthritis and Cartilage, Imaging Atlas for Anti Nerve Growth Factor (a-NGF) Studies, Volume 23, S59 - S68.* doi: 10.1016/j.joca.2014.09.002. Jan 2015.
67. **A double-blind, randomized, Phase III, multicenter study in 358 pediatric subjects receiving isotretinoin therapy demonstrates no effect on pediatric bone mineral density.** K B Hoover, C G Miller, N C Galante, C B Langman. *Osteoporosis International*. Doi: 10.1007/s00198-015-3158-2 May 2015
68. **A DXA whole body composition cross-calibration experience: Evaluation with humans, spine and whole Body phantoms.** D. Krueger, J. Libber, J. Sanfilippo, H-J. Yu, B. Horvath, C.G. Miller, N. Binkley. *Journal of Clinical Densitometry*, doi: org/10.1016/j.jocd.2015.04.003 June 2015
69. **OARSI Clinical Trials Recommendations: Hip imaging in clinical trials in osteoarthritis.** G E Gold, F Cicutini, M D Crema, F Eckstein, A Guermazi, R Kijowski, T M Link, E Maheu, J Martel-Pelletier, C G Miller, J-P Pelletier, C G Peterfy, H G Potter, F W Roemer, D J Hunter *Osteoarthritis and Cartilage*. DOI:10.1016/j.joca.2015.03.004 May 2015; 23(5):716-731



## PUBLICATIONS - CONTINUED

---

70. **OARSI Clinical Trials Recommendations: Knee imaging in clinical trials in osteoarthritis.** D J Hunter, RD Altman, F Cicuttini, M D Crema, J Duryea, F Eckstein, A Guermazi, R. Kijowski, TM Link, , J Martel-Pelletier, C G Miller, TJ Mosher, R E Ochoa-Albíztegui, J-P Pelletier, C Peterfy, J-P Raynauld, F Roemer, SM Totterman, G E Gold. Osteoarthritis and Cartilage. DOI:10.1016/j.joca.2015.03.004 · May 2015; 23(5):698-715
71. **OARSI Clinical Trials Recommendations: Hand imaging in clinical trials in osteoarthritis.** D J Hunter, N Arden, F Cicuttini, M D Crema, B Dardzinski, J Duryea, A Guermazi, I K Haugen, M Kloppenburg, E Maheu, C G Miller, J Martel-Pelletier, R E Ochoa-Albíztegui, J-P Pelletier, C Peterfy, F Roemer, G E Gold. Osteoarthritis and Cartilage. DOI:10.1016/j.joca.2015.03.003 May 2015; 23(5):732-746
72. **A DXA Whole Body Composition Cross-Calibration Experience: Evaluation With Humans, Spine, and Whole Body Phantoms.** Diane Krueger, Jessie Libber, Jennifer Sanfilippo, Hui Jing Yu, Blaine Horvarth, Colin G Miller, Neil Binkley. J Clinical Densitometry April 2016 19(2) 220-225
73. **Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint.** Colin G Miller, Cesar C Bogado, Antonio J Nino, Allison R Northcutt, Hui Jing Yu, E Michael Lewicki, G Paul, Alexander R Cobitz, Margaret J Woodall, John P Belizikian, Lorraine A Fitzpatrick. J Clinical Densitometry 2016. <http://dx.doi.org/10.1016/j.jocd.2016.02.003>
74. **Development of an imaging mitigation strategy for patient enrolment in the Tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment.** Frank W. Roemer, Colin G. Miller, Christine R. West, Mark T. Brown, Sarah P. Sherlock, Andrew J. Kompel, Luis Diaz, Nicholas Galante, Michel D. Crema, Ali Guermazi. Journal: Seminars in Arthritis and Rheumatism. May 2017. <http://dx.doi.org/10.1016/j.semarthrit.2017.05.008>

## ABSTRACTS AND PRESENTATIONS (not published)

---

1. **Gravity induced list.** Porter RW, Miller CG. Presented at the International Society for Studies in the Lumbar Spine 1984. **Also presented at the Society of Back Pain Research.**
2. **Neurogenic claudication and root claudication: A trial comparing calcitonin and placebo.** Porter RW, Miller CG. Presented at the International Society for Studies in the Lumbar Spine.
3. **The prediction of fracture of the proximal femur by broadband ultrasonic attenuation.** Miller CG, Porter RW, Palmer SB. Presented at the Sixth International Workshop on Bone and Soft Tissue Densitometry.
4. **The prediction of fracture of the proximal femur by broadband ultrasonic attenuation.** Miller CG, Porter RW, British Orthopaedic Research Society, October 1987.
5. **Osteoporosis and its relationship to home safety.** Miller CG. Invited speaker to the Southern Home Safety Council of Great Britain, September 1989.